Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete …
Y Li, J Yang, A Aguilar, D McEachern… - Journal of medicinal …, 2018 - ACS Publications
Human murine double minute 2 (MDM2) protein is a primary endogenous cellular inhibitor of
the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target. …
the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target. …
Responses of carbon and water use efficiencies to climate and land use changes in China's karst areas
…, C Zhao, Q Tan, Y Li, G Luo, L Wu, F Chen, C Li… - Journal of …, 2023 - Elsevier
It is crucial to determine the factors affecting the carbon use efficiency (CUE) and water use
efficiency (WUE) of vegetation in ecosystems. However, the relationships between climate …
efficiency (WUE) of vegetation in ecosystems. However, the relationships between climate …
Spring photosynthetic phenology of Chinese vegetation in response to climate change and its impact on net primary productivity
…, C Zhao, Q Tan, Y Li, G Luo, L Wu, F Chen, C Li… - Agricultural and Forest …, 2023 - Elsevier
In the context of global warming, the advancement of spring phenology in northern and
temperate regions due to increased temperatures has been widely reported. Early and delayed …
temperate regions due to increased temperatures has been widely reported. Early and delayed …
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
…, WS Helms, LSL Price, JF Zirkelbach, Y Li… - Clinical Cancer …, 2021 - AACR
On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients
with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and …
with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and …
Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders
Inducing protein degradation by proteolysis targeting chimeras (PROTACs) has gained
tremendous momentum for its promise to discover and develop new therapies. Based upon our …
tremendous momentum for its promise to discover and develop new therapies. Based upon our …
FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET exon 14 skipping mutations or alterations
…, R Jin, H Zhao, H Xia, JF Zirkelbach, Y Bi, Y Li… - Clinical Cancer …, 2022 - AACR
The FDA approved capmatinib and tepotinib on May 6, 2020, and February 3, 2021,
respectively. Capmatinib is indicated for patients with metastatic non–small cell lung cancer (…
respectively. Capmatinib is indicated for patients with metastatic non–small cell lung cancer (…
Soil erosion evolution and spatial correlation analysis in a typical karst geomorphology using RUSLE with GIS
Although some scholars have studied soil erosion in karst landforms, analyses of the spatial
and temporal evolution of soil erosion and correlation analyses with spatial elements have …
and temporal evolution of soil erosion and correlation analyses with spatial elements have …
[HTML][HTML] Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies
…, Y Li, Z Han, Y Li, P Zhang, L Yang, Y Li - American journal of …, 2019 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common liver cancer with high morbidity and
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase inhibitors (…
mortality worldwide. Systemic treatments with several multi-targeted tyrosine kinase inhibitors (…
Discovery of a highly potent, cell-permeable macrocyclic peptidomimetic (MM-589) targeting the WD repeat domain 5 protein (WDR5)–mixed lineage leukemia (MLL) …
We report herein the design, synthesis, and evaluation of macrocyclic peptidomimetics that
bind to WD repeat domain 5 (WDR5) and block the WDR5–mixed lineage leukemia (MLL) …
bind to WD repeat domain 5 (WDR5) and block the WDR5–mixed lineage leukemia (MLL) …
FDA approval summary: osimertinib for adjuvant treatment of surgically resected non–small cell lung cancer, a Collaborative Project Orbis Review
…, X Li, PS Mishra-Kalyani, YL Shen, H Xia, Y Li… - Clinical Cancer …, 2021 - AACR
On December 18, 2020, the FDA approved osimertinib as adjuvant therapy in patients with
non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 …
non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 …